Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
BOSTON, MA – April 8, 2025 – Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
PRIME Nexus is a reusable electro-mechanical autoinjector, leveraging Portal’s PRIME needle-free platform. Compatible with 1.0 mL and 2.25 mL pre-filled syringes, Nexus offers a sustainable solution for a wide range of injectable medications and is currently available for feasibility studies.
Attendees are invited to meet with CCO Steven Kaufman for personalized demonstrations and to discuss the device's capabilities. “We’re thrilled to present PRIME Nexus alongside Gerresheimer at the PFS conference,” stated Kaufman. “The surge in injectable therapies, exemplified by GLP-1 drugs, necessitates a shift towards reusable solutions to mitigate the significant waste generated by single-use devices. PRIME Nexus represents a forward-thinking approach to injector technology.”
For companies traveling to Boston, the Portal team extends an invitation to visit their Cambridge office for a closer look at their technology.
Today Portal Instruments announced a joint publication with Regeneron on the PRIME needle-free injection platform. The findings provided crucial data on Portal's platform, demonstrating the ability to deliver high-viscosity biologics with volume flexibility and tailored injection depths.
August 29, 2024 - Patrick Anquetil talks with Ryan Cote on the Manufacturer's Mindset Podcast. They discuss insights, challenges, and the lessons learned on the journey of revolutionizing needle-free injections at Portal Instruments.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Please fill out the details below and we will get back to you shortly.